Reduction of Fasciculations in Patients With Amyotrophic Lateral Sclerosis With the Use of Gabapentin

• Published in: Archives of neurology (Chicago) Vol. 53; no. 8; p. 716
• Main Author: Romano, Jose G
• Format: Journal Article
• Language: English
• Published: United States American Medical Association 01.08.1996
• Subjects: Acetates - therapeutic use; Amines; Amyotrophic Lateral Sclerosis - drug therapy; Anticonvulsants - therapeutic use; Cyclohexanecarboxylic Acids; Fasciculation - drug therapy; Gabapentin; gamma-Aminobutyric Acid; Humans
• ISSN: 0003-9942; 2168-6149; 1538-3687; 2168-6157
• DOI: 10.1001/archneur.1996.00550080022006

Glutamate-mediated excitotoxicity is one of the mechanisms responsible for motor neuron damage in amyotrophic lateral sclerosis. Decreased glutamate transport may result in elevated extracellular glutamate levels,1 and both riluzole and gabapentin block presynaptic release of glutamine.2 Riluzole prevents neuronal degeneration in vitro3 and delays progression of disease in patients with amyotrophic lateral sclerosis.4 Fasciculations, a hallmark of amyotrophic lateral sclerosis, are a manifestation of "sick" motor neurons. They typically decrease with progression of the disease.While waiting for riluzole to be made available, we have been using gabapentin for our patients with amyotrophic lateral sclerosis with the expectation that it will act like riluzole in preventing progression of disease. Of 31 patients who were prescribed gabapentin, 10 reported a decrease in fasciculations within 2 weeks of reaching the dose of 300 mg 3 times a day. In 5 of these patients, the reduction was described as